Kimball AB, Papp KA, Reich K, et al. - Via obtaining data from two international multicentre, three-part, double-blinded, randomized controlled phase III studies, researchers tested the safety and effectiveness of tildrakizumab in subgroups from the reSURFACE studies (N = 1,862) that received continuous dosing, higher/lower dosing, treatment interruption/reinitiation and initiation. For this investigation, they rerandomized responders [Psoriasis Area and Severity Index (PASI) ≥ 75%] and partial responders (PASI ≥ 50% to < 75%) in Part 3 of the reSURFACE studies (weeks 28–52 or week 64) who received tildrakizumab 200 mg or 100 mg to the same dosage (T100/T100 or T200/T200), a higher/lower dosage (T100/T200 or T200/T100) or placebo (PBO) (T100/PBO or T200/PBO). The proportion of patients who achieved as-observed PASI 75 responses increased over time among T100/T100 and T200/T200 week-28 partial responders. PASI 75 responses increased from week 32 to week 52 and remained consistent in T200/T100 week-28 responders among T100/T200 week-28 partial responders. Overall, the authors concluded that tildrakizumab maintenance, reinitiation, dose adjustment or initiation was generally good for patients.